Clinical Trial Update: Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial [Phase 3]

View source ↗

Summary

Phase 3 trial assessing high-dose clopidogrel versus standard-dose prasugrel in patients with genotype variation showed reduced platelet reactivity in Acute Cor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• PRASUGREL (prasugrel)

Snippet

Sponsor: Gennaro Sardella | Conditions: Acute Coronary Syndrome | Phase 3 | Status: COMPLETED